Intelligent technology company Inteliquet reported on Monday the launch of a Cooperative Research and Development Agreement (CRADA) with the US Department of Health and Human Services and the National Cancer Institute (NCI), with focus on the genetic causes and treatments of cancer.

Under the CRADA, the principal investigators are Jeremy Miller, PhD, chief technology officer at Inteliquet and Javed Khan, MD, deputy chief, Genetics Branch at NCI.

As part of the research agreement, NCI will develop a clinic-ready, web-based tool using its oncogenomics browser with Inteliquet's proprietary Precision Medicine Platform, which focuses on genetic causes and treatments of cancer.

Through the CRADA, NCI will leverage Inteliquet's Precision Medicine Platform to address the need to rapidly integrate clinical and molecular data, linking genetic variants to drugs, status of US FDA approval as well as clinical trials.